#1 Clinical Trials Search in Europe

Ro7589655

A clinical trial is underway to assess the safety, effectiveness, and other important aspects of NXT007, a new drug designed to treat severe or moderate hemophilia A. This study aims to provide valuable insights into how NXT007 works in patients with this blood clotting disorder, including those with or without factor VIII inhibitors.

Table of Contents

What is NXT007?

NXT007, also known as RO7589655, is a new medication being studied for the treatment of severe or moderate hemophilia A. It is classified as a humanized monoclonal modified IgG4 antibody, which is a type of protein designed to target specific molecules in the body[1]. This medication is being developed as a solution for injection that can be administered subcutaneously (under the skin)[1].

Medical Condition: Hemophilia A

NXT007 is being studied to treat severe or moderate hemophilia A, a genetic bleeding disorder. Hemophilia A is caused by a deficiency in a blood clotting protein called factor VIII (FVIII). People with this condition may experience prolonged bleeding after injuries or surgeries, and in severe cases, may have spontaneous bleeding into joints and muscles[1].

The severity of hemophilia A is determined by the amount of factor VIII in a person’s blood:

  • Severe hemophilia A: Less than 1 IU/dL (international unit per deciliter) of factor VIII
  • Moderate hemophilia A: Between 1 and 5 IU/dL of factor VIII

Some people with hemophilia A may develop inhibitors, which are antibodies that interfere with the treatment of the condition. NXT007 is being studied for use in patients both with and without these inhibitors[1].

How NXT007 Works

While the exact mechanism of action is not fully described in the provided information, as a monoclonal antibody, NXT007 is designed to target specific proteins in the blood clotting process. It aims to improve blood clotting in people with hemophilia A, potentially reducing the frequency and severity of bleeding episodes[1].

Clinical Trial Objectives

The ongoing clinical trial for NXT007 has several objectives[1]:

  1. Main objective: To evaluate the safety of multiple doses of NXT007
  2. Secondary objectives:
    • To study how NXT007 behaves in the body (pharmacokinetics) after multiple doses
    • To evaluate the body’s immune response to NXT007 (immunogenicity)
    • To monitor the occurrence or recurrence of factor VIII inhibitors
    • To explore how effective NXT007 is in treating hemophilia A

Eligibility Criteria

The study has specific criteria for who can participate. Here are some key inclusion criteria[1]:

  • Body weight: Participants must weigh at least 40 kg (about 88 pounds)
  • Gender: Only males (based on sex at birth) can participate
  • Diagnosis: Participants must have severe or moderate congenital hemophilia A, with or without inhibitors against factor VIII
  • Treatment history: For participants with inhibitors, they must be using or willing to switch to a specific treatment (recombinant activated factor VII) for breakthrough bleeds

There are also several exclusion criteria, including[1]:

  • Having other inherited or acquired bleeding disorders
  • Being at high risk for a condition called thrombotic microangiopathy (TMA)
  • Having a history of blood clots or certain heart conditions
  • Having severe allergies to similar types of treatments

Study Design

The clinical trial for NXT007 is designed in several phases[1]:

  1. Screening period: This occurs from 28 to 2 days before the start of treatment
  2. Eligibility confirmation: Participants attend a visit to confirm they meet all criteria
  3. Main treatment period: This lasts for 24 weeks (168 days) and includes a planned dose-escalation scheme
  4. Optional extension period: Participants can choose to continue treatment beyond the initial 24 weeks
  5. Safety follow-up period: For participants who don’t continue to the extension period or who stop the treatment early

Safety and Effectiveness Measures

The study will measure several outcomes to assess the safety and effectiveness of NXT007[1]:

  • Safety measures:
    • Monitoring the occurrence and severity of side effects
    • Checking for changes in laboratory test results, vital signs, and heart activity (ECG)
  • Effectiveness measures:
    • Measuring the concentration of NXT007 in the blood over time
    • Monitoring for the development of antibodies against NXT007
    • Tracking the number of bleeding events over time
    • Calculating the annualized bleeding rate (ABR) for different types of bleeds

This clinical trial aims to provide important information about the safety and potential effectiveness of NXT007 in treating severe or moderate hemophilia A. If successful, it could offer a new treatment option for people living with this challenging condition.

Aspect Details
Drug Name NXT007 (RO7589655)
Condition Severe or Moderate Hemophilia A
Study Phase Phase I/II
Main Objective Evaluate safety of multiple doses
Secondary Objectives Assess pharmacokinetics, immunogenicity, efficacy
Key Inclusion Criteria Males, ≥40 kg, severe or moderate hemophilia A
Key Exclusion Criteria Other bleeding disorders, high risk for thrombotic microangiopathy
Primary Endpoints Adverse events, changes in lab results, vital signs, ECG
Secondary Endpoints Pharmacokinetics, antibody development, bleeding events
Study Duration 24 weeks main treatment, optional extension period

FAQ

  • What is NXT007? NXT007 is a new drug being tested for the treatment of severe or moderate hemophilia A. It is a humanized monoclonal modified IgG4 antibody, which means it's a specially designed protein that may help with blood clotting in hemophilia patients.
  • Who can participate in this clinical trial? The trial is open to males (based on sex at birth) with severe or moderate hemophilia A, with or without factor VIII inhibitors. Participants must weigh at least 40 kg and meet other specific criteria set by the researchers.
  • What is the main goal of this study? The main goal of this study is to evaluate the safety of multiple doses of NXT007 in patients with severe or moderate hemophilia A. Researchers will also look at how the body processes the drug, its effectiveness, and how the immune system responds to it.
  • How long does the trial last? The main treatment period lasts for 24 weeks (168 days). After this, there's an optional extension period where participants can continue treatment. The total duration may vary depending on when the drug becomes commercially available.
  • What will researchers measure during the trial? Researchers will monitor several factors, including the occurrence and severity of side effects, changes in laboratory test results, vital signs, and ECG parameters. They'll also track the number of bleeding events, how well the drug prevents bleeding, and whether patients develop antibodies against the drug or factor VIII.

Ongoing Clinical Trials on Ro7589655

  • Study on the Safety and Effects of NXT007 for Patients with Severe or Moderate Hemophilia A

    Recruiting

    1 1 1
    Investigated drugs:
    Italy Poland Spain

  • A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Hungary Italy +3

Glossary

  • Hemophilia A: A genetic disorder that affects blood clotting, caused by a lack of clotting factor VIII. It can lead to excessive bleeding after injuries or surgeries.
  • Factor VIII (FVIII): A protein in the blood that helps with clotting. People with hemophilia A have low levels of this protein or it doesn't work properly.
  • Inhibitors: Antibodies that the body sometimes produces against factor VIII, making standard treatments less effective.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body. In this case, NXT007 is a monoclonal antibody designed to help with blood clotting.
  • Pharmacokinetics: The study of how the body processes a drug, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and effectiveness.
  • Annualized Bleeding Rate (ABR): A measure used to determine how often a person with hemophilia experiences bleeding events over a year.
  • Immune Tolerance Induction (ITI): A treatment approach used to eliminate inhibitors in hemophilia patients by giving regular doses of factor VIII.
  • Bethesda Unit (BU): A measurement used to quantify the level of factor VIII inhibitors in the blood.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-nxt007-for-patients-with-severe-or-moderate-hemophilia-a/